The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).
 
Peter C. Enzinger
Consulting or Advisory Role - Amgen; Five Prime Therapeutics; Pfizer; Sirtex Medical; Taiho Pharmaceutical
 
Nadine Jackson McCleary
No Relationships to Disclose
 
Hui Zheng
No Relationships to Disclose
 
Thomas Adam Abrams
No Relationships to Disclose
 
Matthew B. Yurgelun
Research Funding - Myriad Genetics
 
Christopher G. Azzoli
Honoraria - Boehringer Ingelheim
 
James M. Cleary
No Relationships to Disclose
 
Douglas Adam Rubinson
No Relationships to Disclose
 
Gabriel Brooks
No Relationships to Disclose
 
Jennifer A. Chan
No Relationships to Disclose
 
Lipika Goyal
No Relationships to Disclose
 
Jeffrey A. Meyerhardt
Research Funding - Biothera (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst)
 
Kimmie Ng
No Relationships to Disclose
 
Deborah Schrag
Consulting or Advisory Role - New Century Health; Ohio State University
Other Relationship - JAMA-Journal of the American Medical Association
 
Diane M. F. Savarese
No Relationships to Disclose
 
Christopher Graham
No Relationships to Disclose
 
Margaret M. Carey
No Relationships to Disclose
 
Charles S. Fuchs
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Celgene; Genentech/Roche; Gilead Sciences; Lilly; Macrogenics; MedImmune; MedImmune; Merck; Momenta Pharmaceuticals; Pfizer; Pharmacyclics; Sanofi; Takeda; Vertex